From: Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer
No TNF use (Group 1) | TNF use pre PCa diagnosis (Group 2) | p Value | |
---|---|---|---|
Number | 119814 | 390 | |
Age at Dx [mean(SD)] | 65.76 (8.14) | 64.96 (6.85) | 0.052 |
Less than 55 | 8379 (7.0%) | 20 (5.1%) | 0.179 |
55–64 | 49546 (41.4%) | 174 (44.6%) | 0.21 |
65–74 | 43316 (36.2%) | 159 (40.8%) | 0.066 |
75 and Up | 18573 (15.5%) | 37 (9.5%) | 0.001 |
Race | < 0.001 | ||
African American | 32655 (27.3%) | 56 (14.4%) | |
White | 82894 (69.2%) | 323 (82.8%) | |
Other | 1318 (1.1%) | 6 (1.5%) | |
Unknown | 2947 (2.5%) | 5 (1.3%) | |
T Stage 1 | 78899 (65.9%) | 286 (73.3%) | 0.002 |
T Stage 2 | 36839 (30.7%) | 98 (25.1%) | 0.019 |
T Stage 3 or 4 | 4075 (3.4%) | 6 (1.5%) | 0.059 |
Gleason 6 | 48261 (40.3%) | 172 (44.1%) | 0.138 |
Gleason 7 | 47878 (40.0%) | 162 (41.5%) | 0.56 |
Gleason 8 or Higher | 23690 (19.8%) | 56 (14.4%) | 0.009 |
Mean pre diagnostic PSA (SD) | 18.15 (71.59) | 8.60 (11.99) | 0.011 |
Median pre diagnostic PSA | 6.55 | 5.5 | |
PSA over 20 at Dx | 12253 (11.4%) | 23 (6.3%) | 0.003 |
N Stage 1 | 1965 (1.6%) | 6 (1.5%) | 1 |
M Stage 1 | 4840 (4.0%) | 9 (2.3%) | 0.108 |